Navigation Links
China Botanic Announces Progress on its SOX 404 Compliance Program
Date:12/21/2010

HARBIN, China, Dec. 21, 2010 /PRNewswire-Asia-FirstCall/ -- China Botanic Pharmaceutical Inc. (AMEX: CBP) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that the Company has made considerable progress in its efforts to comply with the requirements of Article 404 of the Sarbanes-Oxley Act ("SOX 404") for fiscal year 2010.

As announced earlier on May 27, 2010, China Botanic engaged PricewaterhouseCoopers ("PwC") to review its internal controls and to provide the corresponding recommendations for gaps/issues noted for fiscal year 2010. Since then, the Company has undergone four rounds of testing and improvements of its internal controls based on PwC's recommendations. Additional details on this ongoing process and the interim results of the initiative will be published in the Company's annual report for its fiscal year ended on October 31, 2010.  

"We are committed to good corporate governance, and our SOX 404 compliance program is an important element in strengthening internal controls," said Mr. Shaoming Li, Chairman and Chief Executive Officer of China Botanic. "To-date, all noted deficiencies are being remediated. Additional details on the internal control remedial actions will be published in the Company's annual report for its fiscal year ending on October 31, 2010. Management has established the necessary procedures to further enhance the relevant areas, and it is our goal to be fully compliant by the end of our fiscal 2011 as required by regulation. "

ABOUT CHINA BOTANIC PHARMACEUTICAL INC. China Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China.  All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China.

Safe Harbor StatementThis press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to the Company's ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.Company Contact: China Botanic Pharmaceutical Inc.Ms. Portia Tan, IR Contact Tel: 86-451-8260-2162Email: ir@renhuang.com CCG Investor Relations:Mr. Mark Collinson, PartnerPhone: +1-310-954-1343 (Los Angeles)Email: mark.collinson@ccgir.comWebsite: www.ccgirasia.comMr. Crocker Coulson, PresidentPhone: +1-646-213-1915 (New York)Email: crocker.coulson@ccgir.com
'/>"/>

SOURCE China Botanic Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. China Botanic Appoints David Dong as New Chief Financial Officer
2. Food and Drug Law Institute to Hold Historic Conference on U.S.-China Food and Drug Law
3. China Botanic Achieves Three Million RMB Sales of New Product
4. China Botanic Sees Strong Initial Demand from Guangzhou Military Region
5. NeoStem Announces Agreement With Shijiazhuang Third Hospital in the Provincial Capital of Hebei Province, China to Offer Orthopedic Applications Based on NeoStem’s Licensed Technology
6. Reportlinker Adds China Pharmaceutical Market Overview
7. NYSE Amex Accepts China Shenghuos Compliance Plan for Continued Listing
8. China-Biotics Attended National Probiotics Seminar
9. China Medical Technologies, Inc. Announces the Closing of US$150 Million Convertible Senior Note Offering and the Completion of Repurchase of US$105.9 Million Convertible Notes Due 2011
10. China Medical Technologies Announces its Subsidiaries, GP Medical and Beijing Yuande, Ranked 12th and 415th, respectively, in Deloitte Technology Fast 500 Asia Pacific 2010 Program
11. Recent NDRC Pricing Concessions Not Expected to Impact China Sky Ones Portfolio of Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, ... -based mobile pulmonary function testing company, is now able to perform ... developed by ndd Medical Technologies , Inc. ... in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL ... can get any needed testing done in the comfort of her ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
Breaking Medicine News(10 mins):